Drug Approval | December 14, 2024
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Final decision from the European Commission is anticipated within the coming months
Final decision from the European Commission is anticipated within the coming months
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Subscribe To Our Newsletter & Stay Updated
